Precision Therapy Based on Immune Microenvironment by Transcriptome Sequencing of Osteosarcoma, a Prospective, Multi-cohort Exploratory Clinical Study

Sponsor
Peking University People's Hospital
Study ID
NCT06776198
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Osteosarcoma
  • Precision Medicine
  • Transcriptome
  • Tumor Microenvironment

Eligibility Criteria

Sex
ALL
Age
8 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Chemotherapy — DRUG
    Group IE/F: After progression, try LRRC15 ADC + PD-1 inhibitors; Group IE: After progression, try simple anti-PD-1 inhibitors; Group F: After progression, try LRRC15 ADC; Group D: After progression, try B7-H3 ADC or other irrinotecan analogue

Study Details

Bagaev et al. have identified four tumor microenvironment (TME) subtypes that are conserved across diverse cancers and correlated with immunotherapy response in melanoma, bladder, and gastric cancers. They provided a visual tool revealing the TME subtypes integrated with targetable genomic alterations, which provided a planetary view of each tumor that can aid in oncology clinical decision making. We aim to use this tool to prospectively analyse the biopsy specimens of osteosarcomas to identify their TME subtypes so as to deliver appropriate treatment strategy if these osteosarcomas experience disease progression afterwards. We will compare the past sequencing date stored in PKUPH bank so as to compare the event-free survival(EFS) of these patients to check the Superiority of this method later.

Key Dates

First listed
Jan 15, 2025
Start date
Mar 1, 2025
Status verified
Jan 2025
Primary completion
Mar 1, 2026
Completion
Jun 1, 2027

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Immune-Enriched, Fibrotic Group (IE/F)
  • Arm: Immune-Enriched, Non-Fibrotic Group (IE)
  • Arm: Fibrotic Group (F)
  • Arm: Depleted Group (D)

Primary Outcome Measure

Event-free Survival (EFS) [ Time Frame: 2 year ]

Central Contacts

Related Studies